ライフサイエンスコーパス: type 2 DM

1 l antimicrobials in patients with type 1 and type 2 DM.

2 tion are similar in patients with type 1 and type 2 DM.

3 or function in subjects with both type 1 and type 2 DM.

4 The prevalence of type 1 DM and type 2 DM was compared between patients with incident RA

5 years with hypertension (>130/80 mm Hg) and type 2 DM (glycosylated hemoglobin [HbA1c], 6.5%-8.5%) a

6 s (peanuts, soybeans, and other legumes) and type 2 DM incidence.

7 In obesity and type 2 DM, there is an increased content of lipid within

8 and to the pathogenesis of both obesity and type 2 DM.

9 pect of IR of skeletal muscle in obesity and type 2 DM.

10 luded proximal myotonic myopathy (PROMM) and type 2 DM (DM2) but without the DM1 mutation, showed lin

11 No association between RA and type 2 DM was observed.

12 rvival in patients with type 1 DM (T1DM) and type 2 DM (T2DM) following CABG.

13 and in combination, which was designated as "type 2 DM phenotype" (n=5).

14 There is a modest association between type 2 DM and CRC among men, but not women.

15 When we allowed for interaction between type 2 DM and other key risk factors, DM remained a sign

16 nhibitor, is regulated in skeletal muscle by type 2 DM and ischemia.

17 p and 402 men in the placebo group developed type 2 DM (relative risk, 0.98; 95% confidence interval,

18 significantly increased risk for developing type 2 DM that is not completely explained by obesity.

19 hus have a 10% annualized risk of developing type 2 DM.

20 were included (199 for type 1 DM and 144 for type 2 DM, and 38 from other sources) if they involved h

21 insulin resistance is the major etiology for type 2 DM and numerous evidences showed that HCV infecti

22 esistance, characterized by risk factors for type 2 DM, can predict islet graft survival in type 1 DM

23 Risk factors for type 2 DM, such as positive family history of type 2 DM

24 Predisposition for type 2 DM can coexist with the type 1 DM phenotype and i

25 rength was associated with a 3-fold risk for type 2 DM (adjusted hazard ratio, 3.07 [CI, 2.88 to 3.27

26 associated with increased long-term risk for type 2 DM, even among those with normal body mass index.

27 pendently associated with increased risk for type 2 DM.

28 Of these patients, 1731 (27.9%) had type 2 DM.

29 risk of incident CRC compared to not having type 2 DM (RR: 1.24; 95% CI: 1.08-1.44); risk was higher

30 ith LV systolic and diastolic dysfunction in type 2 DM; this may explain in part the relationship of

31 sedentary lifestyle and a marked increase in type 2 DM among children.

32 review recent findings that indicate that in type 2 DM and obesity, skeletal muscle manifests inflexi

33 moderate streptozotocin injection to induce type 2 DM.

34 However, data linking type 2 DM risk and legume intake are limited.

35 the prevention of type 2 diabetes mellitus (type 2 DM).

36 Among men, type 2 DM was associated with increased risk of incident

37 Thirty-three percent of type 1 and 48% of type 2 DM patients had significant stenosis (> or = 70%)

38 We investigated associations of type 2 DM and insulin use with CRC risk.

39 -years of follow-up, there were 507 cases of type 2 DM.

40 Improved glycemic control of type 2 DM is associated with substantial short-term symp

41 aboratory data, as well as family history of type 2 DM (first degree relatives), were collected from

42 ype 2 DM, such as positive family history of type 2 DM (n=11) and overweight (body mass index >25 kg/

43 Neither positive family history of type 2 DM nor overweight at baseline could predict islet

44 We followed 64,227 women with no history of type 2 DM, cancer, or cardiovascular disease at study re

45 solute difference in cumulative incidence of type 2 DM between the lowest and highest tertiles of bot

46 Incidence of type 2 DM did not differ between groups: 396 men in the

47 ta-carotene supplementation and incidence of type 2 DM persisted despite multivariate adjustment.

48 the involvement of E2 in the pathogenesis of type 2 DM and underlying mechanisms were investigated in

49 otein indeed involved in the pathogenesis of type 2 DM by inducing insulin resistance.

50 The multivariate-adjusted relative risk of type 2 DM for the upper quintile compared with the lower

51 rm exposure to air pollution and the risk of type 2 DM.

52 The RR of type 2 DM associated with long or highly irregular menst

53 ge 18 to 22 years, the relative risk (RR) of type 2 DM among women with a menstrual cycle length that

54 volving insulin use in adults with type 1 or type 2 DM from January 1, 1980, to January 8, 2003.

55 in 120 outpatients (240 eyes) with type 1 or type 2 DM.

56 Overall, type 2 DM is still relatively infrequent; however, the h

57 Overall, type 2 DM was still relatively infrequent, but the highe

58 e and soy food consumption and self-reported type 2 DM.

59 ular, was inversely associated with the risk type 2 DM.

60 ears had no effect on the risk of subsequent type 2 DM.

61 Approaches to screening renal disease in the type 2 DM population should incorporate assessment of GF

62 r, when both risk factors were grouped, the "type 2 DM phenotype" was associated with earlier islet g

63 , respectively) were examined in relation to type 2 DM identified from outpatient and inpatient diagn

64 ntensity exercise is normal in uncomplicated type 2 DM but is impaired in those with microvascular co

65 227 with type 2 DM) and 1242 women (108 with type 2 DM) were diagnosed with colon or rectal cancer by

66 rs; mean body mass index, 32 [SD, 5.1]) with type 2 DM (mean duration, 7.7 [SD, 7.2] years; mean glyc

67 he final analytic cohort; 1567 men (227 with type 2 DM) and 1242 women (108 with type 2 DM) were diag

68 verall, 13% (sampled n = 171) of adults with type 2 DM (n = 1197) had CRI with a population estimate

69 The population estimate of adults with type 2 DM and CRI in the absence of diabetic retinopathy

70 e both absent in 30% (n = 51) of adults with type 2 DM and CRI.

71 Among older adults with type 2 DM, femoral neck BMD T score and FRAX score were

72 34 008 men were diagnosed with type 2 DM in 39.4 million person-years of follow-up.

73 opic changes to ensure that individuals with type 2 DM and CRI not due to diabetic glomerulosclerosis

74 filtration rate (GFR) among individuals with type 2 DM may not always be due to classic diabetic glom

75 l periodontal treatment of participants with type 2 DM and moderate to severe periodontal disease imp

76 Sixty participants with type 2 DM and moderate to severe periodontal disease wer

77 6; 95% CI: 1.05-1.78), and participants with type 2 DM not using insulin (RR: 1.22, 95% CI: 1.04-1.45

78 1.44); risk was higher for participants with type 2 DM using insulin (RR: 1.36; 95% CI: 1.05-1.78), a

79 d hemoglobin (HbA1c) levels of patients with type 2 DM (DMt2).

80 araoxon in serum samples of 87 patients with type 2 DM and 46 patients with pre-DM showing impaired f

81 In patients with type 2 DM and CP, local delivery of 1% ALN into periodon

82 at 2 years was assessed in 187 patients with type 2 DM and stable coronary artery disease on maintena

83 external validation cohort of patients with type 2 DM but not in an external validation cohort of pa

84 ntrolled, multicenter trial in patients with type 2 DM conducted at 28 clinical sites in the multirac

85 PON-1 status in patients with type 2 DM may contribute to this association.

86 Patients with type 2 DM undergoing bioprosthetic valve implantation ar

87 ithm successfully matched 1113 patients with type 2 DM with the same number of no-DM patients.

88 consent from the patients, 37 patients with type 2 DM without overt heart disease and 23 age-matched

89 In patients with type 2 DM, adding bedtime neutral protamine Hagedorn (is

90 n 18-month treatment period in patients with type 2 DM, pioglitazone slowed progression of CIMT compa

91 roteinase (MMP)-2 and MMP-9 on patients with type 2 DM.

92 egimen that is well suited for patients with type 2 DM.

93 logic regimens for the at-risk patients with type 2 DM.

94 substantial burden of CRI among persons with type 2 DM in the United States is likely due to renal pa

95 ived from soy beans and their products) with type 2 DM was not significant.

96 rsus 2.9% (n=33) in patients with or without type 2 DM (P<0.001), respectively.

97 Among women, type 2 DM and insulin use were not associated with risk